Insight Molecular Diagnostics Inc.
For the period ended Sep 30, 2025. Filed Nov 10, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 10, 2025
IMDX$2.50+0.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
CONDENSED CONSOLIDATED BALANCE SHEETS
| September 30,2025 | December 31,2024 | |
|---|---|---|
| (Unaudited) | ||
| ASSETS | ||
| CURRENT ASSETS | ||
| Cash and cash equivalents | $18,692 | $8,636 |
| Accounts receivable, net of allowance for credit losses of $3 and $16, respectively | 258 | 1,613 |
| Inventories | 471 | 410 |
| Deferred financing costs | — | 279 |
| Restricted cash, current | 729 | — |
| Prepaid expenses and other current assets | 1,239 | 821 |
| Total current assets | 21,389 | 11,759 |
| NONCURRENT ASSETS | ||
| Right-of-use and financing lease assets, net | 2,340 | 2,757 |
| Machinery and equipment, net, and construction in progress | 4,147 | 3,567 |
| Intangible assets, net | 14,600 | 14,607 |
| Restricted cash, noncurrent | 789 | 1,700 |
| Other noncurrent assets | 672 | 691 |
| TOTAL ASSETS | $43,937 | $35,081 |
| LIABILITIES AND SHAREHOLDERS’ DEFICIT | ||
| CURRENT LIABILITIES | ||
| Accounts payable | $1,056 | $2,279 |
| Accrued compensation | 2,228 | 1,939 |
| Accrued royalties | 1,120 | 1,116 |
| Accrued expenses and other current liabilities | 602 | 418 |
| Right-of-use and financing lease liabilities, current | 1,598 | 1,295 |
| Contingent consideration liabilities, current | 1,056 | 228 |
| Total current liabilities | 7,660 | 7,275 |
| NONCURRENT LIABILITIES | ||
| Right-of-use and financing lease liabilities, noncurrent | 1,529 | 2,369 |
| Contingent consideration liabilities, noncurrent | 43,944 | 37,711 |
| TOTAL LIABILITIES | 53,133 | 47,355 |
| Commitments and contingencies (Note 6) | ||
| SHAREHOLDERS’ DEFICIT | ||
| Preferred stock, no par value, 5,000 shares authorized; no shares issued and outstanding | — | — |
| Common stock, no par value, 230,000 shares authorized; 28,625 and 17,453 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively | 368,524 | 338,244 |
| Accumulated other comprehensive income | 86 | 21 |
| Accumulated deficit | (377,806) | (350,539) |
| Total shareholders’ deficit | (9,196) | (12,274) |
| TOTAL LIABILITIES AND SHAREHOLDERS’ DEFICIT | $43,937 | $35,081 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.